Depending on your treatment history, TECENTRIQ can be taken alone or with other medicines
TECENTRIQ was studied in 2 clinical trials with over 1500 people with metastatic NSCLC.
Median overall survival (OS)
Median OS=the length of time from the start of treatment in a clinical trial that half of the patients are still alive.
ALK=anaplastic lymphoma kinase; EGFR=epidermal growth factor receptor.
*Other medicines=bevacizumab + carboplatin + paclitaxel.
†Chemotherapy=carboplatin + paclitaxel.
TECENTRIQ may not work for everyone.
Median progression-free survival: The amount of time that half the people lived without their tumors growing or spreading was 7 months for those not taking TECENTRIQ. That time is compared with 8.5 months for those taking TECENTRIQ + other medicines.*
‡In other words, the cancer was reduced or could no longer be detected on a scan.
§Paclitaxel protein-bound is also referred to as nab-paclitaxel (nab-pac).
TECENTRIQ may not work for everyone.
Median overall survival (OS)
Median OS=the length of time from the start of treatment in a clinical trial that half of the patients are still alive.
*For non-squamous NSCLC, chemotherapy consisted of either cisplatin or carboplatin followed by pemetrexed. For squamous NSCLC, chemotherapy consisted of cisplatin/carboplatin + gemcitabine.
TECENTRIQ may not work for everyone.
Median overall survival (OS)
Median OS=the length of time from the start of treatment in a clinical trial that half of the patients are still alive.
*Docetaxel.
§Paclitaxel protein-bound is also referred to as nab-paclitaxel (nab-pac).
TECENTRIQ may not work for everyone.
Possible serious side effects with TECENTRIQ include, but are not limited to, lung problems, intestinal problems, liver problems, hormone gland problems, kidney problems, skin problems, problems in other organs, severe infusion reactions, and complications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic).
You can learn more about the signs and symptoms of these and other side effects in the TECENTRIQ Medication Guide.
Mary Ann is navigating the challenges of living with metastatic non-small cell lung cancer. Hear how she and her family are determined to face the challenges head on.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.